We are live on ! Find out more
CGEM icon

Cullinan Oncology

148 hedge funds and large institutions have $490M invested in Cullinan Oncology in 2025 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 44 increasing their positions, 51 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

1% more funds holding

Funds holding: 146148 (+2)

9% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 23

2.1% less ownership

Funds ownership: 112.62%110.53% (-2.1%)

14% less repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 51

26% less call options, than puts

Call options by funds: $142K | Put options by funds: $193K

39% less capital invested

Capital invested by funds: $799M → $490M (-$309M)

44% less funds holding in top 10

Funds holding in top 10: 95 (-4)

Holders
148
Holders Change
+2
Holders Change %
+1.37%
% of All Funds
1.98%
Holding in Top 10
5
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-44.44%
% of All Funds
0.07%
New
25
Increased
44
Reduced
51
Closed
23
Calls
$142K
Puts
$193K
Net Calls
-$51K
Net Calls Change
+$844K
Name Holding Trade Value Shares
Change
Change in
Stake
FCMV
26
Foresite Capital Management VI
California
$4.8M
TFCP
27
Twin Focus Capital Partners
Massachusetts
$4.51M
Deutsche Bank
28
Deutsche Bank
Germany
$4.36M -$44.2K -4,605 -0.8%
Marshall Wace
29
Marshall Wace
United Kingdom
$4.3M -$803K -83,694 -13%
Bank of America
30
Bank of America
North Carolina
$3.97M +$3.54M +369,115 +238%
Northern Trust
31
Northern Trust
Illinois
$3.66M -$163K -17,019 -3%
Morgan Stanley
32
Morgan Stanley
New York
$3.65M -$1.5M -156,237 -24%
Charles Schwab
33
Charles Schwab
California
$3.21M -$64.4K -6,709 -2%
Renaissance Technologies
34
Renaissance Technologies
New York
$2.75M +$1.66M +172,500 +91%
UBS Group
35
UBS Group
Switzerland
$2.11M +$414K +43,106 +18%
AAA
36
Affinity Asset Advisors
New York
$2M
Barclays
37
Barclays
United Kingdom
$1.83M -$37.3K -3,888 -2%
AG
38
Algert Global
California
$1.68M +$1.71M +178,138 +411%
N
39
Nuveen
North Carolina
$1.42M -$374K -39,003 -17%
VC
40
Voss Capital
Texas
$1.32M +$505K +52,639 +43%
Wellington Management Group
41
Wellington Management Group
Massachusetts
$1.22M +$269K +28,081 +21%
Bank of New York Mellon
42
Bank of New York Mellon
New York
$1.03M -$11.5K -1,202 -0.9%
BNP Paribas Financial Markets
43
BNP Paribas Financial Markets
France
$982K +$141K +14,721 +13%
American Century Companies
44
American Century Companies
Missouri
$853K +$115K +11,949 +12%
WP
45
Woodline Partners
California
$619K -$821K -85,574 -51%
Acadian Asset Management
46
Acadian Asset Management
Massachusetts
$618K +$784K +81,721 New
Citigroup
47
Citigroup
New York
$613K +$3.14K +327 +0.4%
UBS AM
48
UBS AM
Illinois
$608K -$110K -11,439 -12%
PA
49
Perceptive Advisors
New York
$606K +$769K +80,100 New
Susquehanna International Group
50
Susquehanna International Group
Pennsylvania
$601K +$419K +43,702 +122%

CGEM Hedge Fund Activity: Q1 2025 in Review

148 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Cullinan Oncology (CGEM) for Q1 2025, worth a combined $490M — down 39% from $799M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new CGEM positions and 23 closed out — a net gain of 2 holders — while 44 added to existing stakes and 51 trimmed.

The largest buyer was Lynx1 Capital Management, adding an estimated $18.8M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $12.6M sold.

  • 148 institutional investors held Cullinan Oncology (CGEM) as of Q1 2025, up from 146 in Q4 2024.
  • Funds reported $490M of Cullinan Oncology stock for Q1 2025, down 39% quarter-over-quarter.
  • 25 funds opened new Cullinan Oncology positions in Q1 2025 and 23 closed out, a net change of +2 holders.
  • The largest Cullinan Oncology buyer in Q1 2025 was Lynx1 Capital Management, an estimated $18.8M added.
  • The largest Cullinan Oncology seller in Q1 2025 was Adage Capital Partners, an estimated $12.6M sold.

Based on aggregated 13F filings for Q1 2025.